Welcome to the CCO Site

Thank you for your interest in CCO content. As a guest, please complete the following information fields. These data help ensure our continued delivery of impactful education. 

Become a member (or login)? Member benefits include accreditation certificates, downloadable slides, and decision support tools.

Submit

Key Studies Influencing My Practice Following EACS 2021—Dr. Jürgen Rockstroh

October 27-30, 2021; London, United Kingdom
Hear from expert faculty as he presents his unique insights on some of the most clinically relevant new data presented at EACS 2021, including first-line, switch, and long-acting ART, the efficacy of COVID-19 vaccinations in PWH, and more.
Jürgen K. Rockstroh, MD
Released: November 19, 2021

Information on this Educational Activity

Faculty

Jürgen K. Rockstroh, MD

Professor of Medicine
University Hospital Bonn
Department of Medicine I
Bonn, Germany

Jürgen K. Rockstroh, MD, has disclosed that he has received consulting fees from Abivax, Galapagos, Gilead Sciences, Merck, and ViiV and fees for non-CME/CE services from Gilead Sciences, Janssen, Merck, Theratechnologies and ViiV.

Program Medium

This program has been made available online.

Related Content

Slides from CCO: Discussion of the implications and considerations of polypharmacy and cardiovascular risk on choice of ART in older PWH

Jonathan Appelbaum, MD, FACP, AAHIVS Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Commentary from Dr Jason Halperin on the use of 2-drug ART for rapid start, from Clinical Care Options (CCO)

Jason Halperin, MD, MPH Released: November 29, 2021

Slides from CCO: Discussion of key data and recommendations for choosing ART regimens for patients with virologic failure and resistance

W. David Hardy, MD Josep M. Llibre, MD, PhD Released: November 29, 2021

Perspective on ART modification to reduce CVD risk in PWH, from Dr Jens D. Lundgren and Clinical Care Options (CCO)

Jens D. Lundgren, MD, DMSc Released: November 29, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue